Bemesetron MDL 72222,99.0%

产品编号:Bellancom-B1541| CAS NO:40796-97-2| 分子式:C15H17Cl2NO2| 分子量:314.21

Bemesetron (MDL 72222) 是一种选择性 5-HT3 受体拮抗剂,IC50 为 0.33 nM 。具有神经保护作用。

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-B1541
1200.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

Bemesetron MDL 72222

产品介绍 Bemesetron (MDL 72222) 是一种选择性 5-HT3 受体拮抗剂,IC50 为 0.33 nM 。具有神经保护作用。
生物活性

Bemesetron (MDL 72222) is a selective 5-HT3 receptor antagonist with an IC50 of 0.33 nM. Neuroprotective effect.

体外研究

Blockade of 5-HT3 receptor with Bemesetron (MDL7222) reduces hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells. Bemesetron (0.01, 0.1 and 1 μM, 15 hours) and Y25130 (0.05, 0.5 and 5 μM) concentration-dependently reduce the H2O2-induced decrease of MTT reduction showing 74.9±2.4 and 79.0 ±2.5% with 1 μM and 5 μM, respectively, which are maximal effects.
Pretreatment (20 minutes) with Bemesetron (1 μM), Y25130 (5 μM) or MK-801 (10 μM) significantly, but not completely, inhibits the H2O2-induced elevation of [Ca2+]c.
Bemesetron (1 μM, 15 hours) significantly blocks the H2O2-induced increase of caspase-3 immunoreactivity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: Primary cortical neuronal cells
Concentration: 0.01-1 μM
Incubation Time: 20 minutes (pretreatment); 15 hours (post-incubation)
Result: Concentration-dependently reduced the H2O2-induced decrease of MTT reduction showing 74.9±2.4% with 1 μM, which was maximal effect.

Western Blot Analysis

Cell Line: Primary cortical neuronal cells
Concentration: 1 μM
Incubation Time: 15 hours
Result: Blocked significantly the H2O2-induced increase of caspase-3 immunoreactivity.
体内研究
(In Vivo)

Bemesetron (0.1, 1 and 10 mg/kg; i.p.) is used in male adult albino mice. The lowest dose do not cause any significant change in catalepsy. However, Bemesetron (1 mg/kg) causes a significant reduction of catalepsy (from 90 min after Haloperidol), while 10 mg/kg significantly potentiates the phenomenon (from 60 min after Haloperidol). The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male adult albino mice, weighing 26-36 g
Dosage: 0.1-10 mg/kg
Administration: Intraperitoneally injected, 20 min (pretreatment) +180 min (treatment)
Result: Reduced catalepsy significantly at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect.
体内研究

Bemesetron (0.1, 1 and 10 mg/kg; i.p.) is used in male adult albino mice. The lowest dose do not cause any significant change in catalepsy. However, Bemesetron (1 mg/kg) causes a significant reduction of catalepsy (from 90 min after Haloperidol), while 10 mg/kg significantly potentiates the phenomenon (from 60 min after Haloperidol). The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male adult albino mice, weighing 26-36 g
Dosage: 0.1-10 mg/kg
Administration: Intraperitoneally injected, 20 min (pretreatment) +180 min (treatment)
Result: Reduced catalepsy significantly at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect.
体内研究

Bemesetron (0.1, 1 and 10 mg/kg; i.p.) is used in male adult albino mice. The lowest dose do not cause any significant change in catalepsy. However, Bemesetron (1 mg/kg) causes a significant reduction of catalepsy (from 90 min after Haloperidol), while 10 mg/kg significantly potentiates the phenomenon (from 60 min after Haloperidol). The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male adult albino mice, weighing 26-36 g
Dosage: 0.1-10 mg/kg
Administration: Intraperitoneally injected, 20 min (pretreatment) +180 min (treatment)
Result: Reduced catalepsy significantly at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect.
性状Solid
溶解性数据
In Vitro: 

DMSO : 2 mg/mL (6.37 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1826 mL 15.9129 mL 31.8258 mL
5 mM 0.6365 mL 3.1826 mL 6.3652 mL
10 mM --- --- ---
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


风险声明 (欧洲) 25
安全声明 (欧洲) 36
海关编码 2933990090
1. 物质的识别
产品名: Bemesetron
CAS号: 40796-97-2
制造商/供应商: 西域试剂
网站:www.hzbp.cn   邮件:13911702513@139.com
2. 合成/成分数据
产品名: Bemesetron
别名: MDL 72222
分子式: C15H17Cl2NO2
分子量: 314.21
3. 急救措施
吸入后: 如果吸入,移至空气新鲜处,如果呼吸困难,给输氧,如呼吸停止,给予人工呼吸。
皮肤接触后: 用大量的水冲洗,移除污染的衣服和鞋子。
眼睛接触后: 检查并取下隐形眼镜,并用大量的水冲洗;呼叫医生。
吞食后: 如果吞食,用大量纯净水漱口;呼叫医生。
4. 消防措施
适当的灭火剂: 雾状水,二氧化碳,干粉或泡沫。
防护设备: 穿戴自给式呼吸器和防护服,以防止与皮肤和眼睛接触。
5. 泄漏应急处理
安全防范措施: 封锁泄漏区域;穿戴自给式呼吸器,防护服和厚橡胶手套。
清洁/收集措施: 使用液体粘合原料(硅藻土,通用粘合剂)吸取精细粉末;
使用酒精擦洗表面和设备除去污渍;
根据第11条处理被污染的材料。
6. 处理和储存
安全处理说明: 避免吸入和接触皮肤,眼睛及衣物;材料可能略微具有刺激性。
储存: 粉末型式       -20°C   3年;4°C   2年
溶于溶剂       -80°C   6个月;-20°C   1个月
7. 接触控制和个人防护
呼吸设备: NIOSH / MSHA认可的呼吸器。
双手保护: 耐化学腐蚀的橡胶手套。
眼睛防护: 化学安全护目镜。
8. 稳定性和反应活性
稳定性: 按照说明存储是稳定的;避免强氧化剂。
热分解/其他要避免的情况: 避免光和热。
9. 毒性资料
急性毒性: 无可用资料。
主要刺激性影响: 无可用资料。
在皮肤上: 无可用资料。
对眼睛: 无可用资料;可能具有刺激性。
10. 生态资料
一般注意事项: 无可用资料。
11. 废弃处置
按照所在国家,省份,县市和地方的法规处置。
12. 运输信息
正确的运输名称:
非危险品运输: 这种物质被视为非危险品运输。
13. 法规信息
尚未有针对此产品作出的化学安全性评估。
14. 其他信息
这种化学品仅供受过训练的,有经验的研究人员在穿戴适当装备和授权允许的情况下进行操作处理。以上信息基于我们目前的知识被认为是正确的,但只适用于作为有经验人员的指导。请咨询您自己的安全顾问,并遵守当地和国家的安全法规。在任何其他没有被警告的情况下,并不意味着绝对没有危险存在。西域生物技术不承担任何使用这种化学品所造成的损害和责任。2023 西域生物技术版权所有。





~%

40796-97-2结构式

40796-97-2

文献:Merrell Dow Pharmaceuticals Inc. Patent: US4563465 A1, 1986 ;
上游产品  2

下游产品  0

服务热线

13911702513
18601927057

微信客服